Cadent Therapeutics

Luc Therapeutics, formerly known as Cadent Therapeutics, is a precision neuroscience company focused on developing innovative medicines aimed at improving cognitive and motor functions in patients with serious neurological disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in creating allosteric modulators of ion channels to enhance neuronal firing regularity. Its research includes subunit-selective NMDA receptor modulators, which are being investigated for their potential in treating depression, cognitive dysfunction in schizophrenia, and Rett syndrome, as well as other autism spectrum disorders. By employing a precision neuroscience approach that emphasizes target specificity, patient selection, and optimized drug design, Luc Therapeutics aims to deliver first-in-class therapies for movement and cognitive disorders.